Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 8, 2008 - Issue 4
Submit an article Journal homepage
499
Views
77
CrossRef citations to date
0
Altmetric
Review

SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder

Johanna Krause Private Practice for Psychiatry and Psychotherapy, Schillerstr. 11a, D-85521 Ottobrunn, Germany. [email protected]
Pages 611-625 | Published online: 09 Jan 2014

References

  • Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol. Psychiatry57, 1273–1284 (2005).
  • Castellanos FX, Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat. Rev. Neurosci.3, 617–628 (2002).
  • Krause KH, Dresel SH, Krause J, la Fougere C, Ackenheil M. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci. Biobehav. Rev.27, 605–613 (2003).
  • Spencer TJ, Biederman J, Madras BK et al.In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol. Psychiatry57, 1293–1300 (2005).
  • Swanson JM, Kinsbourne M, Nigg J et al. Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol. Rev.17, 39–59 (2007).
  • Valera EM, Faraone SV, Murray KE, Seidman LJ. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol. Psychiatry61, 1361–1369 (2007).
  • Lou HC, Henriksen L, Bruhn P. Focal cerebral hypoperfusion in children with dysphasia and/or attention deficit disorder. Arch. Neurol.41, 825–829 (1984).
  • Lou HC, Henriksen L, Bruhn P, Børner H, Nielsen JB. Striatal dysfunction in attention deficit and hyperkinetic disorder. Arch. Neurol.46, 48–52 (1989).
  • Lou HC, Henriksen L, Bruhn P. Focal cerebral dysfunction in developmental learning disabilities. Lancet335, 8–11 (1990).
  • Zametkin AJ, Nordahl TE, Gross M et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N. Engl. J. Med.323, 1361–1366 (1990).
  • Ernst M, Cohen RM, Liebenauer LL, Jons PH, Zametkin AJ. Cerebral glucose metabolism in adolescent girls with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry36, 1399–1406 (1997).
  • Zametkin AJ, Rapoport JL. Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years? J. Am. Acad. Child Adolesc. Psychiatry26, 676–686 (1987).
  • Matochik JA, Nordahl TE, Gross M et al. Effects of acute stimulant medication on cerebral metabolism in adults with hyperactivity. Neuropsychopharmacology8, 377–386 (1993).
  • Matochik JA, Liebenauer LL, King AC, Szymanski HV, Cohen RM, Zametkin AJ. Cerebral glucose metabolism in adults with attention deficit hyperactivity disorder after chronic stimulant treatment. Am. J. Psychiatry151, 658–664 (1994).
  • Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J. Neurosci.18, 5901–5907 (1998).
  • Ernst M, Kimes AS, London ED et al. Neural substrates of decision making in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry160, 1061–1070 (2003).
  • Schweitzer JB, Lee DO, Hanford RB et al. A positron emission tomography study of methylphenidate in adults with ADHD: alterations in resting blood flow and predicting treatment response. Neuropsychopharmacology28, 967–973 (2003).
  • Sieg KG, Gaffney GR, Preston DF, Hellings JA. SPECT brain imaging abnormalities in attention deficit hyperactivity disorder. Clin. Nucl. Med.20, 55–60 (1995).
  • Rohde LA, Roman T, Szobot C, Cunha RD, Hutz MH, Biederman J. Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-deficit/hyperactivity disorder: a pilot study. Synapse48, 87–89 (2003).
  • Cumyn L, Kolar D, Keller A, Hechtman L. Current issues and trends in the diagnosis and treatment of adults with ADHD. Expert Rev. Neurotherapeutics7, 1375–1390 (2007).
  • Volkow ND, Wang GJ, Fowler JS et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse43, 181–187 (2002).
  • Bannon MJ. The dopamine transporter: role in neurotoxicity and human disease. Toxicol. Appl. Pharmacol.204, 355–360 (2005).
  • Iversen L. Role of transmitter uptake mechanisms in synaptic neurotransmission. Br. J. Pharmacol.41(Suppl. 1), S82–S88 (1971).
  • Giros B, el Mestikawy S, Godinot N et al. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol. Pharmacol.42, 383–390 (1992).
  • Meiergerd SM, Patterson TA, Schenk JO. D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J. Neurochem.61, 764–767 (1993).
  • Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev. Neurosci.4, 13–25 (2003).
  • Giros B, el Mestikawy S, Bertrand L, Caron MG. Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett.295, 149–154 (1991).
  • Ravna AW, Sylte I, Dahl SG. Molecular model of the neural dopamine transporter. J. Comput. Aided Mol. Des.17, 367–382 (2003).
  • Ciliax BJ, Heilman C, Demchyshyn LL et al. The dopamine transporter: immunochemical characterization and localization in brain. J. Neurosci.15, 1714–1723 (1995).
  • Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol. Ther.91, 35–62 (2001).
  • Stahl SM. Neurotransmission of cognition, part 1. Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine. J. Clin. Psychiatry64, 4–5 (2003).
  • Bymaster FP, Katner JS, Nelson DL et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology27, 699–711 (2002).
  • Mozley PD, Stubbs JB, Plössl K et al. Biodistribution and dosimetry of TRODAT-1: a technetium-99m tropane for imaging dopamine transporters. J. Nucl. Med.39, 2069–2076 (1998).
  • Volkow ND, Ding YS, Fowler JS et al. Dopamine transporters decrease with age. J. Nucl. Med.37, 554–559 (1996).
  • Best SE, Sarrel PM, Malison RT et al. Striatal dopamine transporter availability with [123I]β-CIT SPECT is unrelated to gender or menstrual cycle. Psychopharmacology (Berl.)183, 181–189 (2005).
  • Vandenbergh DJ, Persico AM, Hawkins AL et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics14, 1104–1106 (1992).
  • Doucette-Stamm LA, Blakely DJ, Tian J, Mockus S, Mao JI. Population genetic study of the human dopamine transporter gene (DAT1). Genet. Epidemiol.12, 303–308 (1995).
  • Leighton PW, Le Couteur DG, Pang CC et al. The dopamine transporter gene and Parkinson’s disease in a Chinese population. Neurology49, 1577–1579 (1997).
  • Nakatome M, Honda K, Tun Z et al. Genetic polymorphism of the 3 VNTR region of the human dopaminergic function gene DAT1 (human dopamine transporter gene) in the Mongolian population. Hum. Biol.68, 509–515 (1996).
  • Nakamura Y, Koyama K, Matsushima M. VNTR (variable number of tandem repeat) sequences as transcriptional, translational, or functional regulators. J. Hum. Genet.43, 149–152 (1998).
  • Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet354, 2132–2133 (1999).
  • Fischman AJ, Bonab AA, Babich JW et al. Rapid detection of Parkinson’s disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse29, 128–141 (1998).
  • Kung HF, Kim HJ, Kung MP, Meegalla SK, Plössl K, Lee HK. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur. J. Nucl. Med.23, 1527–1530 (1996).
  • Dresel S, Krause J, Krause KH et al. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur. J. Nucl. Med.27, 1518–1524 (2000).
  • Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci. Lett.285, 107–110 (2000).
  • van Dyck CH, Quinlan DM, Cretella LM et al. Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am. J. Psychiatry159, 309–312 (2002).
  • Larisch R, Sitte W, Antke C et al. Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder. Nucl. Med. Commun.27, 267–270 (2006).
  • Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH, Lee JD. Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder. Eur. J. Nucl. Med. Mol. Imaging30, 306–311 (2003).
  • Volkow ND, Wang GJ, Newcorn J et al. Brain dopamine transporter levels in treatment and drug naïve adults with ADHD. Neuroimage34, 1182–1190 (2007).
  • Spencer TJ, Biederman J, Madras BK et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol. Psychiatry57, 1293–1300 (2005).
  • Spencer TJ, Biederman J, Madras BK et al. Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. Biol. Psychiatry62, 1059–1061 (2007).
  • Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol. Psychiatry57, 229–238 (2005).
  • Madras BK, Miller GM, Fischman AJ. The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD). Behav. Brain Res.130, 57–63 (2002).
  • Volkow ND, Wang GJ, Newcorn J et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry64, 932–940 (2007).
  • Rosa Neto P, Lou H, Cumming P, Pryds O, Gjedde A. Methylphenidate-evoked potentiation of extracellular dopamine in the brain of adolescents with premature birth: correlation with attentional deficit. Ann. NY Acad. Sci.965, 434–439 (2002).
  • Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol. Psychiatry57, 1397–1409 (2005).
  • Chen CK, Chen SL, Mill J et al. The dopamine transporter gene is associated with attention deficit hyperactivity disorder in a Taiwanese sample. Mol. Psychiatry8, 393–396 (2003).
  • Cook EH Jr, Stein MA, Krasowski MD et al. Association of attention-deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet.56, 993–998 (1995).
  • Cornish KM, Manly T, Savage R et al. Association of the dopamine transporter (DAT1) 10/10-repeat genotype with ADHD symptoms and response inhibition in a general population sample. Mol. Psychiatry10, 686–698 (2005).
  • Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol. Psychiatry2, 311–313 (1997).
  • Waldman ID, Rowe DC, Abramowitz A et al. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am. J. Hum. Genet.63, 1767–1776 (1998).
  • Kirley A, Hawi Z, Daly G et al. Dopaminergic system genes in ADHD: toward a biological hypothesis. Neuropsychopharmacology27, 607–619 (2002).
  • Cheon KA, Ryu YH, Kim JW, Cho DY. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur. Neuropsychopharmacol.15, 95–101 (2005).
  • van Dyck CH, Malison RT, Jacobsen LK et al. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J. Nucl. Med.46, 745–751 (2005).
  • Krause J, Dresel SH, Krause KH, La Fougère C, Zill P, Ackenheil M. Striatal dopamine transporter availability and DAT-1 gene in adults with ADHD: no higher DAT availability in patients with homozygosity for the 10-repeat allele. World J. Biol. Psychiatry7, 152–157 (2006).
  • Heinz A, Goldman D, Jones DW et al. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology22, 133–139 (2000).
  • Jacobsen LK, Staley JK, Zoghbi SS et al. Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am. J. Psychiatry157, 1700–1703 (2000).
  • Martinez D, Gelernter J, Abi-Dargham A et al. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology24, 553–560 (2001).
  • Krause J, la Fougere C, Krause KH, Ackenheil M, Dresel SH. Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. Eur. Arch. Psychiatry Clin. Neurosci.255, 428–431 (2005).
  • Kooij JS, Boonstra AM, Vermeulen SH et al. Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1). Am. J. Med. Genet. B Neuropsychiatr. Genet. PMID: 17955457 (2007) (Epub ahead of print).
  • Winsberg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J. Am. Acad. Child Adolesc. Psychiatry38, 1474–1477 (1999).
  • Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz MH. Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics12, 497–499 (2002).
  • Kirley A, Lowe N, Hawi Z et al. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet.121, 50–54 (2003).
  • van der Meulen EM, Bakker SC, Pauls DL et al. High sibling correlation on methylphenidate response but no association with DAT1–10R homozygosity in Dutch sibpairs with ADHD. J. Child Psychol. Psychiatry46, 1074–1080 (2005).
  • Lott DC, Kim SJ, Cook EH Jr, de Wit H. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology30, 602–609 (2005).
  • Stein MA, Waldman ID, Sarampote CS et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology30, 1374–1382 (2005).
  • Ujike H, Harano M, Inada T et al. Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J.3, 242–247 (2003).
  • Gelernter J, Kranzler HR, Satel SL, Rao PA. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology11, 195–200 (1994).
  • Dresel SH, Kung MP, Plössl K, Meegalla SK, Kung HF. Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc]TRODAT-1 to the central dopamine transporters in rats. Eur. J. Nucl. Med.25, 31–39 (1998).
  • Volkow ND, Wang GJ, Fowler JS et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry155, 1325–1331 (1998).
  • Vles JS, Feron FJ, Hendriksen JG, Jolles J, van Kroonenburgh MJ, Weber WE. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics34, 77–80 (2003).
  • Feron FJ, Hendriksen JG, van Kroonenburgh MJ et al. Dopamine transporter in attention-deficit hyperactivity disorder normalizes after cessation of methylphenidate. Pediatr. Neurol.33, 179–183 (2005).
  • Spencer TJ, Biederman J, Ciccone PE et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am. J. Psychiatry163, 387–395 (2006).
  • Krause KH, Krause J. Is akathisia a frequent side effect of neuroleptics in patients with attention deficit/hyperactivity disorder? Anesth. Analg.103, 507–508 (2006).
  • Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K, Ackenheil M. Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder. Int. J. Neuropsychopharmacol.5, 111–113 (2002).
  • Gerasimov MR, Franceschi M, Volkow ND, Rice O, Schiffer WK, Dewey SL. Synergistic interactions between nicotine and cocaine or methylphenidate depend on the dose of dopamine transporter inhibitor. Synapse38, 432–437 (2000).
  • Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature382, 255–257 (1996).
  • Salokangas RK, Vilkman H, Ilonen T et al. High levels of dopamine activity in the basal ganglia of cigarette smokers. Am. J. Psychiatry157, 632–634 (2000).
  • Fowler JS, Volkow ND, Wang GJ et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature379, 733–736 (1996).
  • Fowler JS, Volkow ND, Wang GJ et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl Acad. Sci. USA93, 14065–14069 (1996).
  • Middleton LS, Cass WA, Dwoskin LP. Nicotinic receptor modulation of dopamine transporter function in rat striatum and medial prefrontal cortex. J. Pharmacol. Exp. Ther.308, 367–377 (2004).
  • Court JA, Lloyd S, Thomas N et al. Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience87, 63–78 (1998).
  • Staley JK, Krishnan-Sarin S, Zoghbi S et al. Sex differences in [123I]β-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse41, 275–284 (2001).
  • Conners CK, Levin ED, Sparrow E et al. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol. Bull.32, 67–73 (1996).
  • Greenbaum L, Kanyas K, Karni O et al. Why do young women smoke? I. Direct and interactive effects of environment, psychological characteristics and nicotinic cholinergic receptor genes. Mol. Psychiatry11, 312–322 (2006).
  • Pomerleau CS, Pomerleau OF, Snedecor SM, Gaulrapp S, Kardia SL. Heterogeneity in phenotypes based on smoking status in the Great Lakes Smoker Sibling Registry. Addict. Behav.29, 1851–1855 (2004).
  • Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-basedsample of young adults. Arch. Gen. Psychiatry62, 1142–1147 (2005).
  • Newberg A, Lerman C, Wintering N, Ploessl K, Mozley PD. Dopamine transporter binding in smokers and nonsmokers. Clin. Nucl. Med.32, 452–455 (2007).
  • Yang YK, Yao WJ, Yeh TL et al. Decreased dopamine transporter availability in male smokers – a dual isotope SPECT study. Prog. Neuropsychopharmacol. Biol. Psychiatry32, 274–279 (2008).
  • Wilens TE, Spencer TJ, Biederman J et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am. J. Psychiatry158, 282–288 (2001).
  • Linnet KM, Dalsgaard S, Obel C et al. Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. Am. J. Psychiatry160, 1028–1040 (2003).
  • Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S. Case–control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy. J. Am. Acad. Child Adolesc. Psychiatry41, 378–385 (2002).
  • Loland CJ, Norgaard-Nielsen K, Gether U. Probing dopamine transporter structure and function by Zn2+-site engineering. Eur. J. Pharmacol.479, 187–197 (2003).
  • Pifl C, Rebernik P, Kattinger A, Reither H. Zn2+ modulates currents generated by the dopamine transporter: parallel effects on amphetamine-induced charge transfer and release. Neuropharmacology46, 223–231 (2004).
  • Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. BMC Psychiatry4, 9 (2004).
  • Bilici M, Yildirim F, Kandil S et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry28, 181–190 (2004).
  • Schmitt GJ, Frodl T, Dresel S et al. Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci.256, 115–121 (2006).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.